Telegram RegisterThe public register of Telegram
Telegram profile photo for 리가켐바이오 IR/PR 공식 채널

Channel

리가켐바이오 IR/PR 공식 채널

@SHIDGL

On this record: Topic · Growth · Engagement · What this channel posts · Reactions · Posts · Citations · Cite this entry

10,129subscribers

-34 since we began measuring on 6 August 2026

Risers and fallers across the register · movement among entries of 10,000–31,623.

Register entry

Telegram ID-1001239680246
TypeChannel
Username@SHIDGL
Description리가켐바이오(141080) IR/PR 공식 채널입니다. 리가켐바이오 홈페이지: https://ligachembio.com/
Created2 May 2019measured — cross-checked against a third-party dataset (ext.tg_channel)
First recorded6 August 2026
Last confirmed live23 August 2026
Measurements held16
Confirmed unchanged1 time, most recently 23 August 2026
On Telegramt.me/SHIDGL

Topic

Other / unclassifiable — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-UD-Q6_K_XL, prompt version 1) read this channel’s own recent posts on 15 August 2026 and assigned it the closest of 31 fixed categories, at 97% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.

Growth

10,12910,16310,1466 August 2026 — 10,163 subscribers6 August 2026 — 10,162 subscribers7 August 2026 — 10,161 subscribers8 August 2026 — 10,163 subscribers9 August 2026 — 10,162 subscribers10 August 2026 — 10,161 subscribers11 August 2026 — 10,159 subscribers12 August 2026 — 10,154 subscribers13 August 2026 — 10,152 subscribers14 August 2026 — 10,147 subscribers16 August 2026 — 10,146 subscribers17 August 2026 — 10,143 subscribers18 August 2026 — 10,141 subscribers19 August 2026 — 10,137 subscribers20 August 2026 — 10,132 subscribers23 August 2026 — 10,129 subscribers6 August 202623 August 2026
16 measurements spanning 17 days, net -34. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 10,124–10,168 and does not start at zero.
Measurement log — every subscribers count we have recorded
Measured (UTC)SubscribersChange
23 Aug 2026, 03:2510,129-3
20 Aug 2026, 12:0510,132-5
19 Aug 2026, 12:3910,137-4
18 Aug 2026, 11:4610,141-2
17 Aug 2026, 13:0610,143-3
16 Aug 2026, 03:5710,146-1
14 Aug 2026, 16:1410,147-5
13 Aug 2026, 09:4510,152-2
12 Aug 2026, 11:5510,154-5
11 Aug 2026, 11:2810,159-2
10 Aug 2026, 10:0310,161-1
9 Aug 2026, 08:1210,162-1
8 Aug 2026, 09:4010,163+2
7 Aug 2026, 07:1010,161-1
6 Aug 2026, 09:2110,162-1
6 Aug 2026, 04:5110,163first reading

Engagement

26 posts held, back to 9 July 2026the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 28 pagesof Telegram’s post history, 20 posts per page.

ERR · 30 days
96.2%
avg views ÷ 10,129 subscribers
Avg views / post
9,740
12 posts measured
Reaction rate
0.128%
reactions ÷ views · ER floor
Posts in window
12
of 26 held

ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.

ER is defined industry-wide as (forwards + reactions + comments) ÷ views— note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate. It is computed over the 10 of 12 measured posts that carry a reaction reading, and over those same posts' views.

What these figures were computed from
WindowRolling 30 days · latest post in window 19 August 2026
Posts held26 (9 July 202619 August 2026)
Views total116,920
Reactions total143
Forwards / commentsnot exposed by the public surface — not measured, not estimated
Readings taken24 Aug 2026, 08:51 UTC

Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.

Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.

Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.

What this channel posts

Photos
196
Links
433

Lifetime counters from Telegram’s own channel header, read 24 August 2026 — not the date at the top of this page, which is when the subscriber count was last read. Below Telegram’s rounding threshold, so these counts are exact.

Reaction mix

320 reactions across 20 posts, in 11 distinct kinds. The most used accounts for 31.3% of them.

Every reaction kind recorded on the sample, most used first
ReactionCountShareShare, drawn
10031.3%
👍8426.3%
🔥6921.6%
👀3310.3%
🎉185.63%
👏51.56%
🙏41.25%
🥰41.25%
👌10.313%
😁10.313%
😍10.313%

No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.

Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.

Coverage. Reactions were read on 23 of the 26 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 373reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.

Measured over the 26 most recent posts we hold, published 9 July 2026 to 19 August 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.

Recent posts

19 Aug 2026, 23:43 UTC≈4,380 views21 reactionsread 24 August 2026

암백신 관련하여 당사에서 최근 브리즈바이오와 공동연구 계약 체결한 기사 내용 공유드립니다. https://www.hitnews.co.kr/news/articleView.html?idxno=77764

🔥105👀4👍2

14 Aug 2026, 08:05 UTC≈14,000 views26 reactionsread 24 August 2026

[리가켐바이오 2026년 2분기 실적발표] 안녕하세요 리가켐바이오 IR팀입니다. 조금 전 공시를 통해 당사 2분기 실적을 발표했습니다. 이와 관련한 2분기 실적 IR자료 및 주요 요약 공유드립니다. (2분기 실적 컨퍼런스 콜은 진행되지 않습니다 - 7월 Global R&D Day 행사로 대체, 3분기부터는 다시 컨퍼런스 콜 진행 예정) ■ 2분기 실적 (별도 기준) · 매출액 71억원 / 영업손실 764억원 · 신규 ADC 기술이전 계약 부재 및 후속 마일스톤 유입 제한으로 기술이전 매출 40억원 (-86% YoY) · 연구개발비 765억원 (+90% YoY) — 임상단계 프로젝트 수 확대에 따른 것으로, 연간 연구개발비 증가는 불가피 ■ 3분기 매출 회복 예상 요인 · 오노 LCB97(L1CAM) 첫 환자 투여 마일스톤 수령 확정 (8

14🔥10👀2

7 Aug 2026, 01:57 UTC≈3,620 views8 reactionsread 24 August 2026

안녕하세요 리가켐바이오 IR팀입니다. 금일 조선비즈를 통해 당사가 소티오(SOTIO Biotech)에 ADC 플랫폼 기술이전 이후 도출된 LRRC15 ADC 후보물질 SOT106에 관련한 기사가 나와 공유드립니다. 지난 7월 8일 'LigaChemBio Global R&D Day 2026'을 통해 파트너사 소티오에서 직접 밝힌 바와 같이 8월 중 SOT106의 FDA IND 제출과 연내 첫 환자 투여 개시가 예정되어 있습니다. 참고 부탁드립니다. https://biz.chosun.com/science-chosun/bio/2026/08/07/NRGAECVUTFGIDCDIFUTXC6V45E/?utm_source=naver&utm_medium=original&utm_campaign=biz

4👀2👍1🔥1

7 Aug 2026, 01:35 UTC≈24,000 views16 reactionsread 24 August 2026

[보도자료] 리가켐바이오, B7-H4 ADC 'LNCB74' 단독 개발 권리 확보 - 파트너사 넥스트큐어와 전환·승계 계약 체결…단독개발자(Sole Developing Party) 지위 확보 - 리가켐바이오, 개발·허가·상업화 의사결정권 및 제3자 기술이전 권리 단독 보유 - 진행 중인 글로벌 임상 1상 가속화 기대 ㈜리가켐 바이오사이언스(141080KS, 이하 '리가켐바이오')는 항체 파트너사 넥스트큐어(NextCure, Inc., 이하 '넥스트큐어')와 B7-H4 표적 항체-약물접합체(ADC) 'LNCB74'에 대한 전환·승계 계약(Transition and Continuation Agreement)을 체결하고 해당 프로그램의 단독 개발 권리를 확보했다고 7일 밝혔다. 계약은 미국 현지시간 8월 6일자로 발효됐다. 양사는 2022년 1

10👀2👏2👌1👍1

7 Aug 2026, 01:35 UTC≈1,230 views1 reactionsread 24 August 2026
Forwarded from @darthacking

2026.08.07 10:34:48 기업명: 리가켐바이오(시가총액: 4조 203억) A141080 보고서명: 투자판단관련주요경영사항 (LNCB74(B7H4-ADC) 단독 개발 및 기술이전 권리 확보) 제목 : LNCB74(B7H4-ADC) 단독 개발 및 기술이전 권리 확보 * 주요내용 ※ 투자유의사항 동 계약은 의약품규제기관의 허가가 완료되어야 이행되는 조건부 계약으로서, 본 계약을 통한 수익 인식은 임상시험과 품목허가 등의 성공 여부에 따라 달라질 수 있습니다. 계약 조건에 따라, 규제기관에 의한 연구,개발의 중단, 품목허가 실패 등 발생시 계약이 해지될 수 있습니다. 1) 계약상대방 - NextCure, Inc. - 국적 : 미국 - 설립일 : 2015.09 2) 계약의 내용 : - 양사 공동개발 프로그램인

👀1

5 Aug 2026, 00:35 UTC≈3,230 views18 reactionsread 24 August 2026

안녕하세요 리가켐바이오 IR팀입니다. 금일 하나증권 김선아 위원님께서 지난 주 화~목 3일간 진행된 당사 NDR 이후 '해 뜨기 전의 어두운 새벽을 지나는 중(NDR 후기)'라는 제목의 리포트를 발간해주셔서 자료와 주요 내용 공유드립니다. - 임상 파이프라인 확대: 올해 SOT106(LRRC15), IKS04(CA242), LCB97(L1CAM, Ono)이 임상 1상 진입하며 임상 1상 8개·1/2상 1개·3상 1개로 증가. 연내 임상 진입 예정분 포함 시 10개, '27년에는 13개로 확대 전망 - 하반기 데이터 모멘텀: LCB02A(CLDN18.2) 10월 ESMO, LCB73/IKS03(CD19) 12월 ASH 1a상 중간결과, LCB14/IKS014(HER2) 12월 SABCS 1b상 post-Enhertu 데이터 공개 예상. LCB

👍11🎉32👀1🔥1

4 Aug 2026, 03:14 UTC≈2,140 views14 reactionsread 24 August 2026
Forwarded from @thebio111

리가켐바이오사이언스(이하 리가켐바이오) 창업자인 김용주<사진> 회장이 15억원 규모의 회사 주식을 장내 매수했습니다. 리가켐바이오는 김 회장이 회사 주식 1만7700주를 장내에서 추가 취득했다고 공시했습니다. 평균 매수단가는 주당 8만6106원으로, 총 취득금액은 약 15억2400만원입니다. 이번 매수로 김 회장의 보유 주식수는 기존 122만6428주에서 124만4128주로 늘었습니다. 다만 발행 주식 총수가 증가하면서 지분율은 기존 3.37%에서 3.13%로 낮아졌습니다. 리가켐바이오는 이번 김 회장의 장내 매수에 대해 최근 대외 환경 변화에 따른 주가 하락에도 회사가 확보한 항체약물접합체(ADC) 플랫폼 경쟁력과 파이프라인의 중장기 가치에 대한 확신을 보여주는 ‘책임경영’ 차원의 결정이라고 설명했습니다. https://www.the

12👍1🔥1

4 Aug 2026, 02:46 UTC≈42,000 views14 reactionsread 24 August 2026

[공지] 김용주 회장, 15억원 규모 회사 주식 장내 매수 공시 안녕하세요 리가켐바이오 IR팀입니다. 당사 김용주 회장이 지난 7월 31일(금) 장내에서 회사 주식을 매수함에 따라 조금 전 공시를 통해 공개되어 안내드립니다. - 수량: 17,700주 - 평균 매수단가: 86,106원 - 취득금액: 약 15.2억원 결제일 기준으로 소유 상황이 변동되어, 관련 내용은 금일 임원·주요주주 특정증권등 소유상황보고서로 공시되었습니다. 2006년 창업 이후 20년간 ADC 원천기술 개발을 이끌어온 창업자의 이번 매수는, 최근 매크로 환경 급변에 따른 주가 하락에도 불구하고 회사가 축적해온 플랫폼 경쟁력과 파이프라인의 중장기 가치에 대한 확신을 담은 책임경영 차원의 결정에서 이뤄졌습니다. 당사는 이번 주식 매수 외에도 자체 및 파트너사를 통해 준

9👍2👏1🔥1🥰1

4 Aug 2026, 02:46 UTC≈1,830 views7 reactionsread 24 August 2026
Forwarded from @darthacking

2026.08.04 11:46:02 기업명: 리가켐바이오(시가총액: 4조 18억) A141080 보고서명: 주식등의대량보유상황보고서(일반) 대표보고 : 김 용 주(56년생)/대한민국 보유목적 : 경영권 영향 보고전 : 29.71% 보고후 : 29.62% 보고사유 : 보고자 및 특수관계인의 보유주식 변경 * PAN ORION Corp. Limited 2026-07-24/CB인수(+)/전환사채권/ 350,082주/- * 김용주 2026-08-04/장내매수(+)/보통주/ 17,700주/- 공시링크: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260804000149 회사정보: https://finance.naver.com/item/main.nhn?code=141080

👍4🥰2🔥1

30 Jul 2026, 23:29 UTC≈15,200 views18 reactionsread 24 August 2026

[보도자료] 리가켐바이오, 파트너사 익수다 ‘IKS04’ 美 FDA IND 승인…플랫폼 기술 경쟁력 재입증 - 美 FDA, CA242 타깃 ADC ‘IKS04’ 위장관(GI)암 임상 1상 승인 - 리가켐바이오 프로드러그 플랫폼 적용 파이프라인…IKS014·IKS03 이어 세 번째 임상 진입 - ADC 최초 비접합 항체 병용 ‘IKS04 요법’ 도입…고형암 침투·효능 개선 기대 ㈜리가켐 바이오사이언스(141080KS, 이하 ‘리가켐바이오’)는 파트너사인 익수다 테라퓨틱스(Iksuda Therapeutics, 이하 ‘익수다’)가 리가켐바이오의 ADC 플랫폼 기술이 적용된 CA242 타깃 항체-약물 접합체(ADC) 후보물질 ‘IKS04’에 대해 미국 식품의약국(FDA)으로부터 임상시험계획(IND) 승인을 획득했다고 밝혔다. 이번 승인으로 IKS0

12🔥3👏2👀1

Showing the 12 most recent of 26 posts we hold for @SHIDGL. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.

Citation-graph rank

Citation-graph rank — 315,545 of 1,585,759entries in the measured graph. A weighted position computed from the forward and mention edges below — republished posts weigh more than named mentions — and recomputed periodically, over the whole graph. Published only as this ordinal position, never as a score: a position is a fact, and a score printed beside one channel’s name would read as a verdict this register does not make. The two counts beneath stay separate for the same reason mentions are never summed with forwards anywhere else on this page — a named-by count costs nothing to manufacture. The top 100 by this measure, or how it is computed.

Forward network

Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.

Mentions

Named by 2 registered channels — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.

A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.

Cite this entry

A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 23 August 2026 — this entry's latest reading, not the date you are reading this.

“리가켐바이오 IR/PR 공식 채널” (@SHIDGL), 10,129 subscribers as measured 23 August 2026. Telegram Register, tgregister.com/channel/SHIDGL.

Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.